Analysis of duration of side effects of erlotinib
As a targeted therapy for non-small cell lung cancer, erlotinib has shown significant efficacy during treatment, but patients may also experience a series of side effects during use.
Skin rash is one of the most common side effects of erlotinib, with a high incidence rate. According to data from multiple clinical studies, the median time to appearance of rash is usually around 8 days. This rash is usually mild to moderate and can generally be relieved with appropriate medication and skin care. Its duration varies among individuals, but most patients experience gradual relief over weeks to months.

Diarrhea is also a common side effect of erlotinib, and its incidence is comparable to that of rash. The median onset time of diarrhea is generally about 12 days. For mild diarrhea, patients can control it by adjusting their diet and using antidiarrheal medications. Its duration usually depends on the patient's intestinal sensitivity and response to treatment, with most cases improving within a few weeks.
In addition to rash and diarrhea, erlotinib may also cause a series of other side effects, such as decreased appetite, fatigue, dyspnea, cough, nausea, vomiting, stomatitis, etc. The duration of these side effects varies based on individual differences and specific symptoms. Generally speaking, mild to moderate side effects can be alleviated with appropriate medication and symptomatic support, while severe side effects require prompt medical attention and adjustment of the treatment plan.
Patients who use erlotinib for a long time also need to pay attention to some potential long-term side effects, such as liver function damage and interstitial lung disease (ILD). Liver function impairment usually manifests as asymptomatic elevations in transaminases, so liver function needs to be monitored regularly and adjusted according to physician recommendations. ILD is a more serious side effect. Although its incidence is low, once it occurs, the drug needs to be stopped immediately and corresponding treatment measures need to be taken.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)